Phase 1 trial of lipoplatin and gemcitabine as a second‐line chemotherapy in patients with nonsmall cell lung carcinoma
Authors:
- Marios E. FroudarakisMFMarios E. Froudarakis
- Periklis PappasPPPeriklis Pappas
- Martha NikolaidouMNMartha Nikolaidou
- Demosthenes BourosDBDemosthenes Bouros
Open Access
- 3 November 2008
- Vol. 113 (10) , 2752-2760
Abstract
BACKGROUND.: Lipoplatin is a new liposomal cisplatin that already has been tested in solid tumors, with encouraging results. The purpose of the current study was to determine the maximum tolerated dose (MTD) and the dose‐limiting toxicity (DLT) of a 21‒day regimen of lipoplatin plus a fixed dose of gemcitabine in patients with refractory or resistant nonsmall cell lung carcinoma (NSCLC) with an Eastern Cooperative Oncology Group (ECOG) performance status of ≤2.METHODS.: The lipoplatin dose was escalated at 100 mg/m2 by increments of 10 mg/m2 on Days 1 and 8, with gemcitabine at a dose of 1000 mg/m2 administered on Days 1 and 8, repeated every 21 days. Hematopoietic growth factors were not allowed. Thirteen patients with advanced stage NSCLC who had been pretreated with platinum combination chemotherapy were enrolled in this phase 1 trial. At least 3 patients were entered at each dose level.RESULTS.: At the fourth dose level, the DLT was reached (grade 3 neutropenia [according to World Health Organization criteria] in 3 of 4 patients 75%]; the fourth patient demonstrated degradation of performance status). Therefore, the third dose level (lipoplatin at a dose of 120 mg/m2) was defined as the MTD. At the same dose level, 2 of 4 patients had grade 3 thrombocytopenia. At the fourth dose level, 1 patient achieved a partial response and 1 patient had stable disease. Another patient achieved stable disease at the second dose level. Therefore, the overall disease control rate was 23% (3 of 13 patients). The median overall survival was 29 weeks (range, 4 weeks‐59 weeks) and the median time to disease progression was 12 weeks (range, 3 weeks‐36 weeks).CONCLUSIONS.: The pharmacokinetic profile of the 2 compounds used in the current study are not modified when they are administered according to the schedule evaluated in this trial. When one considers that the patients in the current study had refractory or resistant NSCLC, the authors concluded that the combination of lipoplatin administered at a dose of 120 mg/m2 and gemcitabine administered at a dose of 1000 mg/m2 on Days 1 and 8 every 3 weeks needs to be studied further in phase 2 trials. Cancer 2008. © 2008 American Cancer Society.Keywords
This publication has 22 references indexed in Scilit:
- Response of a Patient with Pleural and Peritoneal Mesothelioma after Second-Line Chemotherapy with Lipoplatin and GemcitabineOncology, 2007
- Combination of chemotherapy without platinum compounds in the treatment of advanced non-small cell lung cancer: A systematic review of phase III trialsLung Cancer, 2005
- Meta-Analysis of Randomized Clinical Trials Comparing Cisplatin to Carboplatin in Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2004
- Gemcitabine and oxaliplatin: a safe and active regimen in poor prognosis advanced non-small cell lung cancer patientsLung Cancer, 2003
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2002
- Global cancer statistics in the year 2000The Lancet Oncology, 2001
- Cellular and molecular determinants of cisplatin resistanceEuropean Journal of Cancer, 1998
- Meta-analysis of randomised trials of systemic chemotherapy versus supportive treatment in non-resectable non-small cell lung cancerLung Cancer, 1995
- Nephrotoxicity mechanism of cis-platinum (II) diamine dichloride in miceToxicology Letters, 1994
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958